RXRX - Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships
2025-02-28 13:17:35 ET
More on Recursion Pharmaceuticals
- Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript
- Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
- Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
- Seeking Alpha’s Quant Rating on Recursion Pharmaceuticals
- Historical earnings data for Recursion Pharmaceuticals